Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and ...

The Ministry of Public Health (MoPH) has advised the public, especially the vulnerable to take the Respiratory Syncytial ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...